|Articles|November 15, 2001
- BioPharm International-11-01-2001
- Volume 14
- Issue 11
Business Matters: Eclipsed by Catastrophe
Author(s)G. Steven Burrill
by G. Steven Burrill at Burrill & Company Despite stimulating and positive news for biotech product approvals and high-value deals this quarter, market performance has been shaped by the terrorist attacks and their aftermath.
Advertisement
Articles in this issue
about 24 years ago
Designs for Bioassays with Plate Location Effectsabout 24 years ago
Liposomes (a Review), Part One: Manufacturing Issuesabout 24 years ago
Simplifying Pharmacologic Analysis with Programmable Scientific Softwareabout 24 years ago
Outsourcing Outlook: Truth in OutsourcingNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies
2
New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models
3
New Lymphoma Indication for CAR T-Cell Therapy Shapes Pipeline
4
Implementing Automation and Flexible Design for Allogeneic Manufacturing
5
